Clinical Trial

Determining the Effect of Abiraterone on the Metabolism of Oxycodone in Men With Prostate Cancer (the ENABLE Study)

Study acronym: ENABLE
Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated June 3, 2025 (before its estimated December 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
Prostate cancer often leads to bone metastases, which require adequate pain management with opioids such as oxycodone. This study investigates whether abiraterone - a drug used in the treatment of prostate cancer - affects the pharmacokinetics of oxycodone in order to improve pain management.
Trial Details
NCT Number NCT07001709
Lead Sponsor Deventer Ziekenhuis
Conditions Prostate Cancer, Pain Cancer
Enrollment 29 participants
Start Date 2024-04-12
Primary Completion 2025-12-30 (estimated)
Study Completion 2026-01-30 (estimated)
Updated on ClinicalTrials.gov 2025-06-03